Several other brokerages also recently commented on TRHC. Zacks Investment Research downgraded shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 22nd. BidaskClub upgraded shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Friday, March 22nd. First Analysis upgraded shares of Tabula Rasa HealthCare from an “outperform” rating to a “strong-buy” rating and set a $58.33 target price for the company in a report on Monday, March 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $99.00 target price on shares of Tabula Rasa HealthCare in a report on Thursday, February 28th. Finally, Oppenheimer lowered their target price on shares of Tabula Rasa HealthCare from $97.00 to $88.00 and set an “outperform” rating for the company in a report on Wednesday, March 6th. Five investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $80.53.
Shares of TRHC stock traded down $2.55 on Monday, hitting $44.24. The stock had a trading volume of 379,700 shares, compared to its average volume of 390,814. The company has a market cap of $1.05 billion, a P/E ratio of 130.12 and a beta of 1.51. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.80 and a quick ratio of 0.79. Tabula Rasa HealthCare has a 12-month low of $43.31 and a 12-month high of $91.16.
In related news, CEO Calvin H. Knowlton sold 8,270 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total transaction of $443,933.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $48.50, for a total transaction of $388,000.00. The disclosure for this sale can be found here. Insiders have sold 48,270 shares of company stock valued at $2,645,294 in the last 90 days. 14.00% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of TRHC. First Mercantile Trust Co. purchased a new stake in Tabula Rasa HealthCare during the fourth quarter worth about $39,000. TCI Wealth Advisors Inc. increased its holdings in Tabula Rasa HealthCare by 1,600.0% during the fourth quarter. TCI Wealth Advisors Inc. now owns 850 shares of the company’s stock worth $54,000 after buying an additional 800 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in Tabula Rasa HealthCare during the fourth quarter worth about $64,000. Neuburgh Advisers LLC increased its holdings in Tabula Rasa HealthCare by 34.9% during the first quarter. Neuburgh Advisers LLC now owns 2,288 shares of the company’s stock worth $129,000 after buying an additional 592 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new stake in Tabula Rasa HealthCare during the fourth quarter worth about $135,000. Institutional investors and hedge funds own 78.60% of the company’s stock.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.